Krensavage Asset Management, LLC Enanta Pharmaceuticals Inc Transaction History

Krensavage Asset Management, LLC

$226 Million
Q1 2024

A detailed history of Krensavage Asset Management, LLC transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Krensavage Asset Management, LLC holds 1,124,586 shares of ENTA stock, worth $14.6 Million. This represents 8.71% of its overall portfolio holdings.

Number of Shares

1,124,586

Previous 742,824 51.39%

Holding current value

$14.6 Million

Previous $6.99 Million 180.9%

% of portfolio

8.71%

Previous 2.48%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$10.08 - $17.46 $3.85 Million - $6.67 Million	381,762 Added 51.39%	1,124,586 $19.6 Million
Q4 2023 Feb 14, 2024	BUY	$8.18 - $10.78 $63,157 - $83,232	7,721 Added 1.05%	742,824 $6.99 Million
Q3 2023 Nov 14, 2023	BUY	$11.09 - $22.13 $526,664 - $1.05 Million	47,490 Added 6.91%	735,103 $8.21 Million
Q2 2023 Aug 11, 2023	BUY	$20.68 - $39.85 $1.74 Million - $3.36 Million	84,312 Added 13.98%	687,613 $14.7 Million
Q1 2023 May 15, 2023	BUY	$38.82 - $54.59 $329,310 - $463,086	8,483 Added 1.43%	603,301 $24.4 Million

Q4 2022 Feb 15, 2023	BUY	$40.77 - $53.73 $222,522 - $293,258	5,458 Added 0.93%	594,818 $27.7 Million
Q3 2022 Nov 14, 2022	SELL	$48.29 - $71.27 $1.71 Million - $2.52 Million	-35,408 Reduced 5.67%	589,360 $30.6 Million
Q2 2022 Aug 16, 2022	BUY	$38.13 - $76.93 $2.9 Million - $5.84 Million	75,940 Added 13.84%	624,768 $29.5 Million
Q1 2022 May 17, 2022	SELL	$56.06 - $74.11 $856,260 - $1.13 Million	-15,274 Reduced 2.71%	548,828 $39.1 Million
Q4 2021 Feb 15, 2022	SELL	$60.19 - $97.37 $22.4 Million - $36.3 Million	-372,675 Reduced 39.78%	564,102 $42.2 Million
Q3 2021 Nov 16, 2021	SELL	$41.02 - $58.65 $117,850 - $168,501	-2,873 Reduced 0.31%	936,777 $53.2 Million
Q2 2021 Aug 13, 2021	BUY	$43.76 - $53.11 $3.36 Million - $4.08 Million	76,802 Added 8.9%	939,650 $41.4 Million
Q1 2021 May 18, 2021	BUY	$41.69 - $54.95 $168,302 - $221,833	4,037 Added 0.47%	862,848 $42.6 Million
Q4 2020 Feb 17, 2021	BUY	$41.16 - $47.47 $1.38 Million - $1.59 Million	33,482 Added 4.06%	858,811 $36.2 Million
Q3 2020 Nov 17, 2020	BUY	$43.36 - $53.53 $2.7 Million - $3.33 Million	62,226 Added 8.15%	825,329 $37.8 Million
Q2 2020 Aug 17, 2020	BUY	$46.37 - $57.58 $2.91 Million - $3.62 Million	62,785 Added 8.97%	763,103 $38.3 Million
Q1 2020 May 18, 2020	BUY	$40.22 - $62.0 $8.48 Million - $13.1 Million	210,933 Added 43.1%	700,318 $36 Million
Q4 2019 Feb 18, 2020	SELL	$57.95 - $66.61 $549,887 - $632,062	-9,489 Reduced 1.9%	489,385 $30.2 Million
Q3 2019 Nov 15, 2019	BUY	$60.08 - $88.17 $1.16 Million - $1.7 Million	19,298 Added 4.02%	498,874 $30 Million
Q2 2019 Aug 14, 2019	BUY	$81.3 - $97.35 $287,314 - $344,034	3,534 Added 0.74%	479,576 $40.5 Million
Q1 2019 May 15, 2019	SELL	$69.08 - $105.66 $4.06 Million - $6.21 Million	-58,783 Reduced 10.99%	476,042 $45.5 Million
Q4 2018 Feb 15, 2019	SELL	$65.41 - $84.65 $68,811 - $89,051	-1,052 Reduced 0.2%	534,825 $37.9 Million
Q4 2018 Feb 14, 2019	BUY	$65.41 - $84.65 $1.62 Million - $2.09 Million	24,691 Added 4.83%	535,877 $44.1 Million
Q3 2018 Nov 14, 2018	SELL	$85.46 - $126.37 $670,775 - $991,878	-7,849 Reduced 1.51%	511,186 $43.7 Million
Q2 2018 Aug 13, 2018	SELL	$81.85 - $120.51 $18.1 Million - $26.6 Million	-220,703 Reduced 29.84%	519,035 $60.2 Million
Q1 2018 May 14, 2018	SELL	$57.91 - $92.15 $7.36 Million - $11.7 Million	-127,032 Reduced 14.66%	739,738 $59.9 Million
Q4 2017 Feb 14, 2018	SELL	$45.65 - $59.37 $6.71 Million - $8.73 Million	-147,077 Reduced 14.51%	866,770 $50.9 Million
Q3 2017 Nov 14, 2017	BUY	$37.91 - $46.8 $38.4 Million - $47.4 Million	1,013,847	1,013,847 $47.4 Million

Others Institutions Holding ENTA

# of Institutions

108

Shares Held

21.7M

Call Options Held

9.4K

Put Options Held

3.3K

View Full List

About ENANTA PHARMACEUTICALS INC

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $269M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

More about ENTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Krensavage Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Krensavage Asset Management, LLC with notifications on news.

Account

Krensavage Asset Management, LLC Enanta Pharmaceuticals Inc Transaction History